1Smith EM,Jayson GC.The current and future management of malignant ascites[J].Clin Oncol,2003,15(2):59-72.
2Takeyoshi I,Iwanami K,Yamada T,et al.Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine:a case report[J].Hepatogastroenterology,2005,52(61):322-325.
3Becker G,Galandi D,Blum HE.Malignant ascites:Systematic review and guideline for treatment[J].European Journal of Cancer,2006,42(5):589-597.
4Tomiyama K,Takahashi M,Fujii T,et al.Improved quality of life for malignant ascites patients by Denver peritoneovenous shuts[J].Anticancer Res,2006,26(3B):2393-2395.
5Namara P.Paracentesis-an effective method of symptom control in the palliative care setting?[J].Palliat Med,2000,14(1):62-64.
6Barnett TD,Rubins J.Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites:a simplified percutaneous approach[J].J Vasc Interv Radiol,2002,13(4):379-383.
7Rosenberg S,Courtney A,Nemcek AA,et al.Comparison of percutaneous management techniques for recurrent malignant ascites[J].J Vasc Interv Radiol,2004,15(10):1129-1131.
8Kuruvilla A,Busby G,Ramsewak S.Intraoperative placement of a self-retaining Foley catheter for continuous drainage of malignant ascites[J].Eur J Gynaecol Oncol,2002,23(1):68-69.
9Brooks RA,Herzog TJ.Long-term semi-permanent catheter use for the palliation of malignant asciets[J].Gynecol Oncol,2006,101(2):360-362.
10Jain KK.Nanotechnology-based drug delivery for cancer[J].Technol Cancer Res Treat,2005,4(4):407-416.
2van der Zee J. Heating the patient : a promising approach. Ann Oncol, 2002,13(8) : 1173-1184.
3Takahashi I, Emi Y, Hasuda S, et al. Clincal application of hyperthernfia combined with anticancer drugs for the treatment of solid tumors. Surgery, 2002,131 (1 Suppl) : S78-S84.
4Westermann AM, Grosen EA, Katschinski DM, et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer, 2001, 37(9) : 1111-1117.
5Rietbroek RC, van de Vaart PJ, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW1573 cells. J Cancer Res Clin Oncol, 1997, 123(1): 6-12.
6Hirohashi Y, Hidaka K, Sato S, et al. Biomodulation by hyperthermia of topoisomeraes II-targeting drug in human colorectal cancer cells. Jpn J Cancer Res, 1995, 86(11): 1097-1105.
7Van Heek-Romanowski R, Putter S, Trarbach T, et al. Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia. Med Pediatr Oncol,2001,36( 1 ) : 197-198.
8Kondo T, Ueda K, Kano E. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse rnmammry carcinoma FM3A cells. Anticancer Res, 1995,15 ( 1 ) : 83-86.
9Nishida Y, Hamaji M, Miyazaki S, et al. Thermochernotherapy using low dose CPT-11 in a patient with local recurrence of rectal cancer. Gan To Kagaku Ryoho, 1999,26(4) :549-552.
10Van Bree C, Beumer C, Rodermond HM, et al. Effectiveness of 2', 2' difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Im J Hyperthermia, 1999,15(6) : 549-556.
